Guillain-Barré syndrome after bortezomib therapy in a child with relapsed acute lymphoblastic leukemia

Valeria Ceolin,Rosita Cenna,Francesca Resente,Manuela Spadea,Franca Fagioli,Nicoletta Bertorello
DOI: https://doi.org/10.1080/08880018.2021.1959691
2021-08-09
Pediatric Hematology and Oncology
Abstract:A 12-year-old male being treated for a high-risk relapsed T-acute lymphoblastic leukemia presented progressive weakness and numbness of both legs after having received a chemotherapy regimen that included bortezomib. Diagnosis of acute Guillain-Barré syndrome-like inflammatory demyelinating polyneuropathy was made following clinical examination, cerebrospinal fluid analysis, electrodiagnostic studies, magnetic resonance imaging, and serum immunoglobulin antibodies to anti-ganglioside. Intravenous immunoglobulin treatment was started, resulting in complete clinical recovery. Although in rare cases, Guillain-Barré syndrome after bortezomib therapy has been reported; this paper suggests that GBS may occur when bortezomib is administered and high‑dose intravenous immunoglobulin lead to a resolution of the symptoms.
oncology,pediatrics,hematology
What problem does this paper attempt to address?